Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions

NCT00939367 | Completed Phase 1 Results

• 1 other identifier: US/05/004
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Subjects to compare the single dose bioavailability of Torrent's Zolpidem Tartrate Tablets 10mg and Ambien® Tablets 10 mg of Sanofi-Synthelabo Inc.

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Maximum Plasma Concentration (Cmax)

  The maximum or peak concentration that the drug reaches in the plasma

  plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.

• Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

  The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t)

  plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.

• The Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity AUC(0-∞)

  The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.

  plasma samples were obtained from blood drawn at 0 (within 60 minutes prior to dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours (18 samples) after administration of the dose.

Study Arms (2)

Test

EXPERIMENTAL

Torrent's Zolpidem TartrateTablets 10 mg

Drug: Zolpidem Tartrate Tablets 10 mg

Reference

ACTIVE COMPARATOR

Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg

Drug: 'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg

Interventions

Zolpidem Tartrate Tablets 10 mg DRUG

Test

'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg DRUG

Reference

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female subjects in the range of 18 - 45 years of age.
• Subjects having Body Mass Index (BMI) in a range of 18.5 to 24.9.
• Subjects with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiration rate and body temperature)
• Subjects with normal findings as determined by hematological tests, serum chemistry, urine analysis, ECG and X-ray.
• Willingness to follow the protocol requirement as evidenced by written, informed consent.
• Agreeing to, not using any medication prescription and over the counter medicines including vitamins and minerals for 14 days prior to study and during the course of the study.
• No history or presence of significant alcoholism or drug abuse in the past one year.
• Non-smokers, ex smokers and light smokers will be included. " Light smokers are defined as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely stopped smoking for at least 3 months.

You may not qualify if:

• Requiring medication for any ailment including enzyme-modifying drugs in the previous 28 days, before day1.
• Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract, blood-forming organs etc.
• History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic diseases.
• Participation in a clinical drug study or bioequivalence study 90 days prior to present study.
• History of malignancy or other serious diseases.
• Refusal to abstain from food for at least ten (10) hours prior to High Fat Breakfast and for additional four (4) hours post dose during each study period.
• Refusal to abstain from water for at least one (1) hour prior to study drug administration on each study period and for at least two (2) additional hours, post dosing.
• Any contraindication to blood sampling.
• Use of xanthine-containing beverages or food and grapefruit juice for 48 hours prior to each drug dose.
• Blood donation 90 days prior to the commencement of the study.
• Subjects with positive HIV tests, HbsAg or Hepatitis-C tests.
• Known history of hypersensitivity to zolpidem Tartrate or to any of the inactive ingredients in the formulation.
• Refusal to abstain from smoking or consumption of tobacco products 24 hours before dosing until last sample collection of each period.
• Pregnant and lactating women.
• Use of prescription medication within 14 days prior to administration of study medication or over the counter products (including natural food supplements,vitamins, garlic as a supplement) within 14 days prior to administration of study medication, except for topical products without systemic absorption.

Sponsors & Collaborators

• Torrent Pharmaceuticals Limited: lead

Study Sites (1)

Accutest Research Laboratories Pvt. Ltd.

Mumbai, Maharashtra, India

Location

MeSH Terms

Interventions

Zolpidem

Intervention Hierarchy (Ancestors)

Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Kedar Joshi
• Organization: Accutest Research Laboratories Pvt. Ltd.

+91 22 27780718

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 13, 2009
• First Posted: July 15, 2009
• Study Start: February 24, 2007
• Primary Completion: May 2, 2007
• Study Completion: May 2, 2007
• Last Updated: June 28, 2018
• Results First Posted: November 14, 2013

Record last verified: 2017-10

Locations

IN (1)